WindTree Therapeutics is officially off the Nasdaq Capital Market because they did not comply with the listing rules. The Nasdaq decision took effect August 21, 2025 and was a result of the company’s which had failed to keep the stock above the $1.00 minimum bid price as required by Rule 5550(a)(2).
WindTree’s shares had traded below this threshold since May 2025, despite attempts to regain compliance. After the delisting, the company expects to move to the over-the-counter (OTC) market under the ticker WINT, though approval is not guaranteed, highlighting the precarious status of WindTree Therapeutics.
Stock Price Collapse
The delisting report which set off a massive sell off in WindTree Therapeutics’ shares. We saw prices drop by almost 80% that day which saw them close at only 11 cents. This marked:.
- Daily decline: On announcement day of 77% drop.
- Monthly loss: Beyond 90% drop in value.
- Year-to-date: Over 99% gone.
Before the announcement the stock was at 48 cents, a significant decrease for WindTree Therapeutics.
The BNB Treasury Gamble
WindTree Therapeutics has only just put out an aggressive plan to create a $200 million BNB treasury which was to see the company transform into a Binance ecosystem player similar to what MicroStrategy did with Bitcoin.
The strategy included:
- A $60M securities agreement with Build and Build Corp.
- An additional $140 million subscription option
- A $500 million line of credit from an institution which is an investor.
- A $20M stock agreement with Build and Build Corp.
Nearly 99% of funds were intended for BNB purchases, supported by a partnership with Kraken for custody and OTC trading.
Ironically, while WindTree Therapeutics collapsed, BNB surged to an all-time high of $880 on the same day, gaining 5.6%.
Core Business And Financial Struggles
Founded in 1992, WindTree Therapeutics is a biopharma company which has developed a portfolio of cardiovascular and pulmonary treatments. Lead product in the pipeline is Istaroxime which has been given Fast Track designation by the FDA for the treatment of acute heart failure also we have in the pipeline assets like Aerosurf and Surfactin.
Despite those assets which they have, WindTree Therapeutics is still burning cash heavily. In the first half of 2025 they reported $5.064 million in operational cash outflows. Also this year the company went into a new revenue strategy via the acquisition of biotech companies, but that did not improve investor sentiment.
Industry Implications
WindTree Therapeutics’ case in point, which goes to show the issue of which companies think to put into crypto treasury models before they have their financials in order. While MicroStrategy’s success with Bitcoin which made it a Wall Street player Wind Tree did not have the stability or the investor trust to make that shift.
The delisting also includes reduced access for institutions in WindTree Therapeutics and at the same time serves as a warning to companies which attempt to replicate crypto balance sheet strategies. Without compliance, market confidence and core business growth digital asset plays may speed up instead of preventing collapse.
